Prognostic Predictors of Response to Hypoglycemic Therapy

NCT03804411 on ClinicalTrials.gov · last registry update 2020-02-10

An unusually large phase 4: 800 participants, more than double the 75 typical for the stage. Its estimated completion date, March 2020, has passed with no update to the record. Primary outcome, as filed: HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Sponsor type: Other
Enrollment: 800
Started: 2017-08-01
Primary completion: 2020-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.